J. Van Cutsem

Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.

Johan R. Boelaert, M. de Locht, J. Van Cutsem et al. · Journal of Clinical Investigation · 1993 · 341 citations · Full text

Deferoxamine Therapy, Antifungal Agent, Fungal Uptake +14

Antimycotic imidazoles. Part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent

Jan Heeres, L. J. J. Backx, J. H. Mostmans et al. · Journal of Medicinal Chemistry · 1979 · 340 citations

Preparation and antimycotic properties of derivatives of 1-phenethylimidazole

Erik F. Godefroi, Jan Heeres, J. Van Cutsem et al. · Journal of Medicinal Chemistry · 1969 · 264 citations

Posttreatment itraconazole levels in the nail

Marcella Willemsen, Piet De Doncker, James P. Willems et al. · Journal of the American Academy of Dermatology · 1992 · 173 citations

Posttreatment Itraconazole Levels, Clinical Dermatology, Dermatology +2

Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect

Johan R. Boelaert, J. Van Cutsem, M. de Locht et al. · Kidney International · 1994 · 167 citations · Full text

Hydroxypyridinone Chelators, Biochemistry, Medicine +6